Corcept Therapeutics Incorporated (CORT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has a cash flow conversion efficiency ratio of -0.026x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.77 Million) by net assets ($637.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CORT net asset quality score to measure how much of total assets are equity-financed.
Corcept Therapeutics Incorporated - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Corcept Therapeutics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Corcept Therapeutics Incorporated to evaluate the quality of earnings relative to operating cash generation.
Corcept Therapeutics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strathcona Resources Ltd.
TO:SCR
|
0.044x |
|
Yunnan Copper Co Ltd
SHE:000878
|
0.056x |
|
Casella Waste Systems Inc
NASDAQ:CWST
|
0.040x |
|
AB Sagax (publ)
ST:SAGA-B
|
0.013x |
|
AMMB Holdings Bhd
KLSE:1015
|
0.007x |
|
Outfront Media Inc
NYSE:OUT
|
0.109x |
|
Kite Realty Group Trust
NYSE:KRG
|
0.033x |
|
Baic Bluepark New Energy Technology
SHG:600733
|
-0.273x |
Annual Cash Flow Conversion Efficiency for Corcept Therapeutics Incorporated (2003–2025)
The table below shows the annual cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see CORT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $647.80 Million | $142.00 Million | 0.219x | -24.79% |
| 2024-12-31 | $679.59 Million | $198.07 Million | 0.291x | +16.25% |
| 2023-12-31 | $506.70 Million | $127.04 Million | 0.251x | +4.57% |
| 2022-12-31 | $501.84 Million | $120.32 Million | 0.240x | -46.33% |
| 2021-12-31 | $375.81 Million | $167.89 Million | 0.447x | +53.85% |
| 2020-12-31 | $523.34 Million | $151.97 Million | 0.290x | -20.81% |
| 2019-12-31 | $371.18 Million | $136.12 Million | 0.367x | -12.53% |
| 2018-12-31 | $275.88 Million | $115.67 Million | 0.419x | +31.39% |
| 2017-12-31 | $190.97 Million | $60.94 Million | 0.319x | -28.21% |
| 2016-12-31 | $41.38 Million | $18.39 Million | 0.444x | +162.67% |
| 2015-12-31 | $18.50 Million | $3.13 Million | 0.169x | -97.91% |
| 2014-12-31 | $-3.39 Million | $-27.38 Million | 8.080x | +558.26% |
| 2013-12-31 | $21.02 Million | $-37.06 Million | -1.763x | -202.41% |
| 2012-12-31 | $61.78 Million | $-36.02 Million | -0.583x | +25.93% |
| 2011-12-31 | $34.81 Million | $-27.40 Million | -0.787x | +24.96% |
| 2010-12-31 | $21.24 Million | $-22.29 Million | -1.049x | -28.98% |
| 2009-12-31 | $22.09 Million | $-17.97 Million | -0.813x | +25.11% |
| 2008-12-31 | $16.91 Million | $-18.36 Million | -1.086x | -45.95% |
| 2007-12-31 | $14.73 Million | $-10.96 Million | -0.744x | +79.63% |
| 2006-12-31 | $6.36 Million | $-23.24 Million | -3.654x | -463.80% |
| 2005-12-31 | $26.59 Million | $-17.23 Million | -0.648x | -117.07% |
| 2004-12-31 | $45.95 Million | $-13.72 Million | -0.299x | +69.43% |
| 2003-12-31 | $10.24 Million | $-10.00 Million | -0.977x | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more